EGFR alterations in glioblastoma play a role in antitumor immunity regulation

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is frequently altered in glioblastoma (GBM).
• Targeted therapies and immunotherapies have shown limited efficacy in GBM patients with EGFR alterations.
• EGFR signaling impacts both tumor development and the anti-tumor immune response.

Purpose of the Study:

• To review the role of EGFR alterations in shaping the glioblastoma tumor microenvironment (TME).
• To explore the mechanisms by which EGFR alterations influence immune components within the TME.
• To provide a rationale for combining EGFR inhibitors with immunotherapy in GBM treatment.

Main Methods:

• Literature review of studies investigating EGFR alterations in glioblastoma.
• Analysis of EGFR's impact on tumor cell proliferation and immune cell recruitment.
• Examination of EGFR's role in upregulating immunosuppressive molecules and cytokines.

Main Results:

• EGFR alterations promote GBM cell proliferation.
• EGFR alterations lead to the recruitment of immunosuppressive cells (M2-like TAMs, MDSCs, Tregs) into the TME.
• EGFR alterations upregulate immunosuppressive factors like PD-L1, CD73, and TGF-β, inhibiting T and NK cell activity.

Conclusions:

• EGFR alterations establish an immunosuppressive TME in glioblastoma.
• Understanding EGFR's immunomodulatory role is crucial for developing effective GBM therapies.
• Combining EGFR-targeted therapies with immunotherapies holds promise for overcoming treatment resistance in GBM.